3,3a,4,5-tetrahydro-2H-benzo[de]chromen-6-one | 188109-88-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 3,3a,4,5-tetrahydro-2H-benzo[de]chromen-6-one
• 英文别名: 2-Oxatricyclo[7.3.1.05,13]trideca-1(12),9(13),10-trien-8-one
• CAS: 188109-88-8
• 化学式: C₁₂H₁₂O₂
• 分子量: 188.226
• InChiKey: UKCFWZILJAUPFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,3a,4,5-tetrahydro-2H-benzo[de]chromen-6-one 在 RaNi 锂丁酯 、 氨 、 氢气 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 甲醇 、 苯 为溶剂， 反应 2.75h， 生成 2-Oxatricyclo[7.3.1.05,13]trideca-1(12),9(13),10-trien-8-ylmethanamine
  参考文献：
  名称：

  Structure−Activity Studies for a Novel Series of N-(Arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines Possessing Dual 5-HT Uptake Inhibiting and α₂-Antagonistic Activities

  摘要：

  In search of an alpha(2)-antagonist/5-HT uptake inhibitor as a potential new class of antidepressant with a more rapid onset of action, compound 3 was prepared and observed to possess high affinity for the alpha(2)-receptor (K-i = 6.71 nM) and the 5-HT uptake site (20.6 nM). A series of tertiary amine analogs of 3 were synthesized and assayed for their affinity at both the alpha(2)-receptor and the 5-HT uptake site. The structure-activity relationship reveals that a variety of structural modifications to the arylethyl fragment are possible with retention of this dual activity. On the tetralin portion, 5-OMe substitution and the (R) stereochemistry at C-l are optimal with alternate substitutions producing compounds retaining high affinity for the alpha(2)-receptor but lacking affinity for the 5-HT uptake site. Data for several rigidified 5-O-alkyl analogs suggests that the favored orientation of the oxygen lone pairs may be away from the g-position of the tetralin.

  DOI：

  10.1021/jm960723m
• 作为产物：
  描述：

  2-(chroman-4-yl)ethyl methanesulfonate 在 四丁基氟化铵 、 水 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 甲苯 、 乙腈 为溶剂， 反应 18.17h， 生成 3,3a,4,5-tetrahydro-2H-benzo[de]chromen-6-one
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS
  [FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL

  摘要：

  本公开提供化合物及其制药组合物。还提供制备和使用这些化合物的方法。这些化合物可以用于调节，例如激活TAAR1，并可用于治疗、预防、诊断和/或管理各种中枢神经系统疾病。

  公开号：

  WO2022204150A1

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
  申请人：BLUE OAK PHARMACEUTICALS INC

  公开号：WO2022204150A1

  公开（公告）日：2022-09-29

  The present disclosure provides compounds and pharmaceutical compositions thereof. Methods of making and using the compounds are also provided. The compounds can be used to modulate such as activate TAAR1 and can be used for the treatment, prevention, diagnosis and/or management of various CNS disorders.

  本公开提供化合物及其制药组合物。还提供制备和使用这些化合物的方法。这些化合物可以用于调节，例如激活TAAR1，并可用于治疗、预防、诊断和/或管理各种中枢神经系统疾病。
• [EN] TRICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉ D'OXASPIRO SUBSTITUÉ TRICYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION PHARMACEUTIQUE<br/>[ZH] 三环取代的氧杂螺环衍生物、其制法与医药上的用途
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD

  公开号：WO2020147848A1

  公开（公告）日：2020-07-23

  提供了一种三环取代的氧杂螺环衍生物、其制法与医药上的用途。具体地，公开了式(I)和式(II)化合物或其药学上可接受的盐、立体异构体或溶剂化物，及其制备方法和应用。
• BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2128154B1

  公开（公告）日：2015-04-08
• US8877779B2
  申请人：——

  公开号：US8877779B2

  公开（公告）日：2014-11-04
• Structure−Activity Studies for a Novel Series of <i>N</i>-(Arylethyl)-<i>N</i>-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-<i>N</i>-methylamines Possessing Dual 5-HT Uptake Inhibiting and α₂-Antagonistic Activities
  作者：Michael D. Meyer、Arthur A. Hancock、Karin Tietje、Kevin B. Sippy、Rajnandan Prasad、David M. Stout、David L. Arendsen、B. Greg Donner、William A. Carroll

  DOI：10.1021/jm960723m

  日期：1997.3.1

  In search of an alpha(2)-antagonist/5-HT uptake inhibitor as a potential new class of antidepressant with a more rapid onset of action, compound 3 was prepared and observed to possess high affinity for the alpha(2)-receptor (K-i = 6.71 nM) and the 5-HT uptake site (20.6 nM). A series of tertiary amine analogs of 3 were synthesized and assayed for their affinity at both the alpha(2)-receptor and the 5-HT uptake site. The structure-activity relationship reveals that a variety of structural modifications to the arylethyl fragment are possible with retention of this dual activity. On the tetralin portion, 5-OMe substitution and the (R) stereochemistry at C-l are optimal with alternate substitutions producing compounds retaining high affinity for the alpha(2)-receptor but lacking affinity for the 5-HT uptake site. Data for several rigidified 5-O-alkyl analogs suggests that the favored orientation of the oxygen lone pairs may be away from the g-position of the tetralin.